Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Island Pharmaceuticals Ltd ( (AU:ILA) ) has issued an announcement.
Island Pharmaceuticals Ltd has progressed significantly in its ISLA-101 Phase 2a/b PROTECT clinical trial for dengue fever, showcasing safety and anti-dengue activity in the Phase 2a prophylactic arm. The company has secured A$3.5 million through a two-tranche investment, ensuring funding for the Phase 2b trial and potential pipeline expansion. With the appointment of Phillip Lynch as Executive Chairman, Island Pharmaceuticals is poised to advance its development initiatives and explore growth opportunities, reinforcing its position in the biotech industry.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on creating treatments for infectious diseases. Its primary product, ISLA-101, is aimed at addressing the unmet need for effective dengue fever treatments.
YTD Price Performance: 2.94%
Average Trading Volume: 231,269
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$31.8M
Learn more about ILA stock on TipRanks’ Stock Analysis page.
